A randomized, double-blind, phase (Ph) III study of the irinotecan-based chemotherapy FOLFIRI plus ramucirumab (RAM) or placebo (PL) in patients (pts) with metastatic colorectal carcinoma (mCRC) progressive during or following first-line therapy with bevacizumab (BEV), oxaliplatin (OXALI), and a fluoropyrimidine (FP) (RAISE) (NCT01183780).
Axel Grothey
Consultant or Advisory Role - Bayer (U); Genentech (U); ImClone Systems (U); Roche (U)
Research Funding - Bayer; Daiichi Sankyo; Genentech
Josep Tabernero
No relevant relationships to disclose
Philippe Rougier
Consultant or Advisory Role - Merck; Sanofi ; SERVIER
Honoraria - Merck; Novartis; Pfizer; Sanofi
Research Funding - Roche
Shaila Ballal
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Heidi Crane
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Mark D. Rutstein
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly